As the member noted, the combination therapies involving bamlanivimab of Eli Lilly and of Regeneron and Roche are before Health Canada, the regulator. The submissions were received in February and are undergoing the expedited review process that I spoke of earlier, under interim order. I can't say when they will be approved, but scientists are working day and night to review the submissions.
On April 16th, 2021. See this statement in context.